1. 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC). (September 2015) Authors: Cho, B.C.; Dy, G.K.; Govindan, R.; Kim, D.W.; Pennell, N.A.; Zalcman, G.; Besse, B.; Nogai, H.; Rajagopalan, P.; Ocker, M.; Barlesi, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies. (December 2016) Authors: Postel-Vinay, S.; Herbschleb, K.; Massard, C.; Woodcock, V.; Ocker, M.; Wilkinson, G.; Walter, A.; Ewerton, F.; Poelman, M.; Middleton, M.; Soria, J.C. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Bernasconi, E.; Gaudio, E.; Lejeune, P.; Tarantelli, C.; Rinaldi, A.; Kwee, I.; Mensah, A.A.; Chung, E.Y.L.; Stathis, A.; Ocker, M.; Zucca, E.; Haendler, B.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗